DEM BioPharma Establishes Leadership Team withAppointment of Nenad Grmusa as CEO andChristophe Quéva, Ph.D., as CSO
CAMBRIDGE, Mass., September 27, 2022-- DEM BioPharma, Inc. (DEM Bio), an oncology company
developing therapies that target signals on cancer cells and macrophages to eliminate tumors,established its C-suite and scientific leadership teams with the appointment of Nenad Grmusa as Chief
Executive Officer and Christophe Quéva, Ph.D., as Chief Scientific Officer. The company simultaneously
announced the prior appointment of Loise Francisco-Anderson, Ph.D., as SVP and Head of Biology. Mr.
Grmusa, Dr. Quéva and Dr. Francisco-Anderson join experienced industry leader John McCabe whoserves as Chief Financial Officer and Chief Operating Officer.
Mr. Grmusa succeeds David Donabedian, Ph.D., Co-founder and start-up Chief Executive Officer of DEM
Bio, and Operating Partner of Longwood Fund, who will continue to serve in an advisory capacity to theCompany.
“We welcome Mr. Grmusa, Dr. Queva and Dr. Francisco-Anderson whose combined expertise inimmuno-oncology, drug discovery and development, business development, and R&D portfolio
management will be critical to our team as we progress DEM Bio forward” said Jan Skvarka, Ph.D.,
Executive Chairman of DEM Bio. “The addition of these three exceptional leaders underscores ourrecent momentum following our successful launch with $70 million in financing in June of 2022 and puts
us in a position to build a leading next-generation immuno-oncology company.”“I am thrilled to join DEM Bio and to work alongside this world-class team of leaders in the emerging
and highly promising field of innate immune system checkpoint inhibitors,” said Mr. Grmusa. “DEM Bio’s
successful launch has positioned the Company to continue pioneering the next generation oftherapeutics.”
Mr. Grmusa brings 20 years of industry experience in business development, pharmaceutical portfolio
management, R&D finance and financial planning and analysis. Prior to joining DEM Bio, Mr. Grmusa led
the R&D Strategy and External Innovation (RSEI) group at Takeda, after supporting the Head of R&D inmanaging Takeda’s diverse pipeline as Head, Center for External Innovation (CEI). Previously, Mr.
Grmusa supported Millennium Pharmaceuticals, Inc. in various financial planning and analytical roles
with increasing responsibilities, and 3 years with Boston Biomedical Consultants. Mr. Grmusa holds anM.A. in International Economics and Finance from Brandeis University and a B.S. in Finance from West
Virginia University.

“The identification of unexplored ‘don’t eat me’ (DEM) signals on cancer cells and macrophages using
DEM Bio’s proprietary CHoMP™ platform (Co-culture with Human Myeloid Phagocytes) has the potential
to enhance cancer cell elimination through increased phagocytosis,” said Dr. Quéva. “I am honored tojoin this team of innovators and work towards the development of immunotherapeutics to target novel
innate immune system checkpoints.”
Dr. Quéva joins DEM Bio with nearly 20 years of experience in successful immuno-oncology portfoliobuilding from target identification through clinical development and regulatory approval. Prior to joining
DEM Bio, Dr. Quéva held the role of Chief Scientific Officer and Senior Vice President, Research atOncorus, Inc. Previously, Dr. Quéva led the generation of an innovative immuno-oncology portfolio ofsmall molecule and antibody programs as the Chief Scientific Officer at iTeos Therapeutics, and has held
successive senior positions at AstraZeneca, Amgen and Gilead Sciences. Dr. Quéva holds a Ph.D. in Lifeand Health Sciences from the University of Lille, France, and trained as a post-doctoral fellow at the Fred
Hutchinson Cancer Research Center in Seattle.
Dr. Francisco-Anderson is an experienced senior leader with a demonstrated history of working within
the biotech industry. She brings to the DEM Bio team 17 years of experience in immuno-oncology, drug
development, oncology, and immunology, with special emphasis in immune checkpoint inhibition anddendritic cell biology. Prior to joining DEM Bio, Dr. Francisco-Anderson held several positions ofincreasing responsibility at Evelo Biosciences, working first as Senior Director of Immuno-oncology
Research and later as VP of Discovery, Innovation and Oncology. Previously, Dr. Francisco-Anderson
served as Scientific Group Leader and Senior Principal Investigator, Immunology, at GSK. Dr. FranciscoAnderson received her Ph.D. in Immunology from the Johns Hopkins University School of Medicine andcompleted her post-doctoral training at Harvard Medical School in the laboratory of Dr. Arlene Sharpe.
“On behalf of the entire board, I would like to thank David for his significant contributions as co-founderand start-up CEO to DEM Bio,” said Christoph Westphal, M.D., Ph.D., Founding CEO, DEM Bio, andFounding Partner of Longwood Fund. “Under David’s leadership, the Company has raised $70 million
and attracted a top tier syndicate of investors, identified incubator lab space and built out the scientificand leadership team. I look forward to working with David on our next Longwood new company.”

About DEM BioPharma Inc.
DEM Bio is pioneering the next generation of immunotherapeutics that unleash the innate immune
system to eliminate tumors by targeting ‘don’t eat me’ (DEM) and ‘eat me’ (EM) signals on cancer cells,macrophages and other myeloid effector cells. Founded by Longwood Fund, the company’s approachbuilds on the groundbreaking functional genomics research and discoveries in macrophage biology fromits scientific co-founders: Drs. Jonathan Weissman and Kipp Weiskopf of the Whitehead Institute and Dr.
Michael Bassik of Stanford University. The proprietary CHoMP™ platform (Co-culture with Human
Myeloid Phagocytes) utilizes CRISPR-based functional genomic screens in human cancer cells and/or
primary macrophages to discover and validate new DEM and EM signals that could profoundly induce
and enhance cancer cell elimination through increased phagocytosis. For further information, see:https://dembiopharma.com/.

Contacts
Kari Watson or Holly Hancock
MacDougall Advisors
kwatson@macdougall.bio or hhancock@macdougall.bio(781) 235-3060